Boston Scientific Sees Grim Q2 But Eyes Growth By Q4 Fueled By Product Launches
Executive Summary
The big news at Boston Scientific's first-quarter earnings call was how badly the pandemic had impacted the second quarter so far, with sales down almost $500m in April. But the company said it already saw signs that procedure volumes were beginning to bounce back.
You may also be interested in...
J&J, Acutus And Boston Scientific Announce Plans For Pulsed Field AF-Ablation Technologies
Pulsed field ablation, which uses a controlled electrical field instead of focused heat or cold, has shown promise as a safer alternative to thermal and cryo approaches for atrial fibrillation ablation.
Boston Scientific Remains On Track For Return To Growth By 2021
The company’s sales declined 29% in the second quarter of 2020 due to the pandemic, but sales trends indicate the start of a worldwide recovery across all of Boston Scientific’s businesses.
Exec Chat: Boston Scientific’s Angelo De Rosa Forsees Digital Transformation In The COVID-19 Era
Angelo De Rosa, VP of Boston Scientific's cardiac rhythm management business in Europe, the Middle East and Africa, talked to Medtech Insight about the opportunities to accelerate digital transformation in health care during the COVID-19 crisis.